ABBOTT INDIA LIMITED
🇮🇳India
- Country
- 🇮🇳India
- Ownership
- Private
- Established
- 1888-01-01
- Employees
- 73K
- Market Cap
- $7.5B
- Website
- http://www.abbott.com
Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2011-04-13
- Lead Sponsor
- Abbott
- Target Recruit Count
- 1469
- Registration Number
- NCT00195676
- Locations
- 🇺🇸
Site Reference ID/Investigator# 1268, Tyler, Texas, United States
🇺🇸Site Reference ID/Investigator# 2434, Columbus, Ohio, United States
🇺🇸Site Reference ID/Investigator# 1683, Boston, Massachusetts, United States
Long Term Safety and Tolerability Study in Approximately 350 Subjects With Moderate to Severe Chronic, Non-malignant Pain
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2011-01-19
- Lead Sponsor
- Abbott
- Target Recruit Count
- 431
- Registration Number
- NCT00195728
- Locations
- 🇺🇸
Site Ref # / Investigator 1813, Clearwater, Florida, United States
🇺🇸Site Reference # / Investigator 1741, Raleigh, North Carolina, United States
🇺🇸Site Reference # / Investigator 1719, Virginia Beach, Virginia, United States
A 16 Week Comparative Study of Fenofibrate Versus Ezetimibe as Add-on Therapy to Atorvastatin
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2007-10-04
- Lead Sponsor
- Abbott
- Target Recruit Count
- 174
- Registration Number
- NCT00195793
Study Designed to Evaluate the Safety of Prophylactic Depakote ER in the Treatment of Adolescents With Migraine
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2007-09-03
- Lead Sponsor
- Abbott
- Target Recruit Count
- 315
- Registration Number
- NCT00195806
- Locations
- 🇺🇸
Global Medical Information - Abbott, North Chicago, Illinois, United States
A Phase III Open-Label, Multi-Center, Long-Term Extension Study of Depakote ER in Subjects Who Either Completed or Prematurely Discontinued Due to Ineffectiveness From Study M02-488.
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2007-07-31
- Lead Sponsor
- Abbott
- Target Recruit Count
- 114
- Registration Number
- NCT00195754
- Locations
- 🇺🇸
Global Medical Information - Abbott, North Chicago, Illinois, United States
A Long-Term Safety Study of Asoprisnil in the Treatment of Uterine Fibroids.
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2009-03-04
- Lead Sponsor
- Abbott
- Target Recruit Count
- 38
- Registration Number
- NCT00156182
A Study to Evaluate the Safety and Effectiveness of Asoprisnil in the Treatment of Uterine Fibroids
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2008-05-29
- Lead Sponsor
- Abbott
- Target Recruit Count
- 129
- Registration Number
- NCT00160459
A Long-Term Study to Evaluate the Safety of Asoprisnil in the Treatment of Women With Endometriosis From Study M01-398
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2008-05-29
- Lead Sponsor
- Abbott
- Target Recruit Count
- 73
- Registration Number
- NCT00160420
Safety of Treatment of Uterine Fibroids With Asoprisnil
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2008-05-29
- Lead Sponsor
- Abbott
- Target Recruit Count
- 166
- Registration Number
- NCT00156208
A Study to Evaluate the Safety and Effectiveness of Three Asoprisnil Doses in the Treatment of Women With Endometriosis
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2008-05-29
- Lead Sponsor
- Abbott
- Target Recruit Count
- 130
- Registration Number
- NCT00160446
© Copyright 2024. All Rights Reserved by MedPath